Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Wang, Enfeng ^a   Bhattacharyya, Sanjib ^a   Szabolcs, Annamaria ^a   Rodriguez Aguayo, Cristian ^b   Jennings, Nicholas B ^b   Lopez Berestein, Gabriel ^b   Mukherjee, Priyabrata ^a   Sood, Anil K ^b   Bhattacharya, Resham ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CASPASE; CISPLATIN; DIOLEOYLPHOSPHATIDYLCHOLINE; GLUTATHIONE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BMI1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; REACTIVE OXYGEN METABOLITE; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; GENE SILENCING; GROWTH INHIBITION; LIPOSOMAL GENE DELIVERY SYSTEM; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR GROWTH; BIOSYNTHESIS; FEMALE; GENETICS; HUMAN; METABOLISM; OVARY TUMOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CISPLATIN; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GLUTATHIONE; HUMANS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS;

EID: 79952824058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017918     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
2. Armstrong DK, (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 (Suppl 5): 20-28.
3. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, et al. (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16 (Suppl 8): viii7-viii12.
4. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, et al. (2007) Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 7: 3-18.
5. Sedletska Y, Giraud-Panis MJ, Malinge JM, (2005) Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 5: 251-265.
6. Lessard J, Sauvageau G, (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260.
7. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R, (2005) Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 19: 1432-1437.
8. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, et al. (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425: 962-967.
9. Raaphorst FM, (2003) Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1. Trends Immunol 24: 522-524.
10. Cui H, Hu B, Li T, Ma J, Alam G, et al. (2007) Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 170: 1370-1378.
11. Hayry V, Tynninen O, Haapasalo HK, Wolfer J, Paulus W, et al. (2008) Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol 34: 555-563.
12. Liu JH, Song LB, Zhang X, Guo BH, Feng Y, et al. (2008) Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 97: 267-272.
13. Sawa M, Yamamoto K, Yokozawa T, Kiyoi H, Hishida A, et al. (2005) BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 82: 42-47.
14. Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, et al. (2007) Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res 9: R55.
15. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, et al. (2006) Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66: 6225-6232.
16. Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, et al. (2008) Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 134: 1037-1042.
17. Wang H, Pan K, Zhang HK, Weng DS, Zhou J, et al. (2008) Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 535-541.
18. Yang GF, He WP, Cai MY, He LR, Luo JH, et al. (2010) Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer 10: 133.
19. Zhang F, Sui L, Xin T, (2008) Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol 30: 70-74.
20. Alkema MJ, Jacobs H, van Lohuizen M, Berns A, (1997) Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger. Oncogene 15: 899-910.
21. Haupt Y, Bath ML, Harris AW, Adams JM, (1993) bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 8: 3161-3164.
22. Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, et al. (2009) BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 28: 3022-3032.
23. Zhang S, Balch C, Chan MW, Lai HC, Matei D, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.
24. Glinsky GV, Berezovska O, Glinskii AB, (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521.
25. Rosenberg B, VanCamp L, Trosko JE, Mansour VH, (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222: 385-386.
26. Helm CW, States JC, (2009) Enhancing the efficacy of cisplatin in ovarian cancer treatment- could arsenic have a role. J Ovarian Res 2: 2.
27. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, et al. (2009) MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer. Cancer Res.
28. Chatoo W, Abdouh M, David J, Champagne MP, Ferreira J, et al. (2009) The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J Neurosci 29: 529-542.
29. Liu J, Cao L, Chen J, Song S, Lee IH, et al. (2009) Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 459: 387-392.
30. Bragado P, Armesilla A, Silva A, Porras A, (2007) Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 12: 1733-1742.
31. Huang HL, Fang LW, Lu SP, Chou CK, Luh TY, et al. (2003) DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 22: 8168-8177.
32. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, et al. (1997) GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 273: G7-17.
33. Buttke TM, Sandstrom PA, (1994) Oxidative stress as a mediator of apoptosis. Immunol Today 15: 7-10.
34. Arrigo AP, (1999) Gene expression and the thiol redox state. Free Radic Biol Med 27: 936-944.
35. Anderson ME, (1998) Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111-112: 1-14.
36. Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, et al. (2005) DNA repair, genome stability, and aging. Cell 120: 497-512.
37. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913.
38. Ahmad S, (2010) Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers 7: 543-566.
39. Borges HL, Linden R, Wang JY, (2008) DNA damage-induced cell death: lessons from the central nervous system. Cell Res 18: 17-26.
40. Thornberry NA, (1998) Caspases: key mediators of apoptosis. Chem Biol 5: R97-103.
41. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, et al. (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918.
42. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, et al. (2008) Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100: 359-372.
43. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, et al. (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407-1427.
44. Ismail IH, Andrin C, McDonald D, Hendzel MJ, (2010) BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 191: 45-60.
45. Li J, Gong LY, Song LB, Jiang LL, Liu LP, et al. (2010) Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. Am J Pathol 176: 699-709.
46. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, et al. (2002) The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62: 4736-4745.
47. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, et al. (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302-305.
48. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, et al. (2009) Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 15: 3770-3780.
49. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, et al. (2008) Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 14: 7659-7666.
50. Mukhopadhyay P, Rajesh M, Hasko G, Hawkins BJ, Madesh M, et al. (2007) Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc 2: 2295-2301.
51. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.